Table 4.
Univariate and multivariate analyses of baseline characteristics predicting complete disability recovery (HAQ < 0.5).
| HAQ < 0.5 (1st year) | Univariate analysis | HAQ < 0.5 (1st year) | Multivariate analysis | ||
|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||
| Age (≥65 versus <65 years) | [0.974 (0.962–0.985)] | <0.0001 | Age (≥65 versus <65 years) | [0.978 (0.965–0.99)] | 0.0004 |
| Gender (F versus M) | [0.354 (0.248–0.505)] | <0.0001 | Gender (F versus M) | [0.417 (0.282–0.617)] | <0.0001 |
| Disease duration (years) | [1.004 (0.985–1.023)] | ns | Disease duration | [0.998 (0.976–1.02)] | ns |
| DAS28 (high versus moderate versus low) | [0.622 (0.542–0.713)] | <0.0001 | DAS28 (high versus moderate versus low) | [0.724 (0.626–0.837)] | <0.0001 |
| DMARDs (no versus yes) | [1.248 (0.724–2.151)] | ns | DMARDs (no versus yes) | [0.85 (0.453–1.596)] | ns |
| Steroids (no versus yes) | [2.109 (1.445–3.078)] | 0.0001 | Steroids (no versus yes) | [1.775 (1.153–2.734)] | ns |
| Adalimumab versus infliximab | [1.495 (1.045–2.138)] | ns | Adalimumab versus infliximab | [1.547 (1.041–2.297)] | 0.0307 |
| Etanercept versus infliximab | [1.048 (0.69–1.59)] | ns | Etanercept versus infliximab | [0.871 (0.538–1.41)] | ns |
|
| |||||
| HAQ < 0.5 (5th year) | Univariate analysis | HAQ < 0.5 (5th year) | Univariate analysis | ||
| OR (95% CI) | P | OR (95% CI) | P | ||
|
| |||||
| Age (≥65 versus <65 years) | [0.978 (0.964–0.991)] | 0.0014 | Age (≥65 versus <65 years) | [0.982 (0.967–0.996)] | 0.0142 |
| Gender (F versus M) | [0.474 (0.31–0.726)] | 0.0006 | Gender (F versus M) | [0.571 (0.362–0.901)] | 0.016 |
| Disease duration | [1.002 (0.979–1.025)] | ns | Disease duration | [0.995 (0.97–1.022)] | ns |
| DAS28 (high versus moderate versus low) | [0.729 (0.624–0.853)] | 0.0001 | DAS28 (high versus moderate versus low) | [0.79 (0.668–0.936)] | 0.0063 |
| DMARDs (no versus yes) | [0.702 (0.322–1.53)] | ns | DMARDs (no versus yes) | [0.627 (0.255–1.54)] | ns |
| Steroids (no versus yes) | [1.851 (1.182–2.898)] | 0.0071 | Steroids (no versus yes) | [1.832 (1.102–3.045)] | 0.0195 |
| Adalimumab versus Infliximab | [0.607 (0.383–0.962)] | ns | Adalimumab versus infliximab | [0.554 (0.337–0.911)] | 0.0199 |
| Etanercept versus infliximab | [0.607 (0.364–1.011)] | ns | Etanercept versus infliximab | [0.502 (0.284–0.888)] | 0.0179 |
OR: odds ratio; CI: confidence interval; F: female; M: male; DMARDs: disease modifying antirheumatic drugs; DAS28: 28-joint disease activity score; HAQ: Health Assessment Questionnaire.